These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3134519)

  • 1. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
    Ackland SP; Choi KE; Ratain MJ; Egorin MJ; Williams SF; Sinkule JA; Bitran JD
    J Clin Oncol; 1988 Jul; 6(7):1192-6. PubMed ID: 3134519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of continuous-infusion high-dose thiotepa.
    Henner WD; Shea TC; Furlong EA; Flaherty MD; Eder JP; Elias A; Begg C; Antman K
    Cancer Treat Rep; 1987 Nov; 71(11):1043-7. PubMed ID: 3119200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    O'Dwyer PJ; LaCreta F; Nash S; Tinsley PW; Schilder R; Clapper ML; Tew KD; Panting L; Litwin S; Comis RL
    Cancer Res; 1991 Nov; 51(22):6059-65. PubMed ID: 1933869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high dose thiotepa in children undergoing autologous bone marrow transplantation.
    Kletzel M; Kearns GL; Wells TG; Thompson HC
    Bone Marrow Transplant; 1992 Aug; 10(2):171-5. PubMed ID: 1525606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
    Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
    de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.
    Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J
    Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
    Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
    Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL
    Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
    Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
    Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/pharmacokinetic reevaluation of thioTEPA.
    O'Dwyer PJ; LaCreta F; Engstrom PF; Peter R; Tartaglia L; Cole D; Litwin S; DeVito J; Poplack D; DeLap RJ
    Cancer Res; 1991 Jun; 51(12):3171-6. PubMed ID: 1710167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.
    Wadler S; Egorin MJ; Zuhowski EG; Tortorello L; Salva K; Runowicz CD; Wiernik PH
    J Clin Oncol; 1989 Jan; 7(1):132-9. PubMed ID: 2491884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
    Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
    Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.
    Williams SF; Bitran JD; Kaminer L; Westbrook C; Jacobs R; Ashenhurst J; Robin E; Purl S; Beschorner J; Schroeder C
    J Clin Oncol; 1987 Feb; 5(2):260-5. PubMed ID: 3027271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
    O'Dwyer PJ; LaCreta FP; Schilder R; Nash S; McAleer C; Miller LL; Hudes GR; Ozols RF
    J Clin Oncol; 1992 Aug; 10(8):1352-8. PubMed ID: 1634926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
    de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
    Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
    Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.